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ABSTRACT: Platinum drugs are widely used for cancer
treatment. Other precious metals are promising, but their
clinical progress depends on achieving diﬀerent mechanisms
of action to overcome Pt-resistance. Here, we evaluate 13
organo-Os complexes: 16-electron sulfonyl-diamine catalysts
[(η6-arene)Os(N,N′)], and 18-electron phenylazopyridine
complexes [(η6-arene)Os(N,N’)Cl/I]+ (arene = p-cymene,
biphenyl, or terphenyl). Their antiproliferative activity does
not depend on p21 or p53 status, unlike cisplatin, and their
selective potency toward cancer cells involves the generation
of reactive oxygen species. Evidence of such a mechanism of
action has been found both in vitro and in vivo. This work appears to provide the ﬁrst study of osmium complexes in the
zebraﬁsh model, which has been shown to closely model toxicity in humans. A ﬂuorescent osmium complex, derived from a lead
compound, was employed to conﬁrm internalization of the complex, visualize in vivo distribution, and conﬁrm colocalization
with reactive oxygen species generated in zebraﬁsh.
■ INTRODUCTION
Cancer is one of the leading causes of death in the developed
world.1,2 As many as half of all cancer chemotherapy regimens
include a platinum drug, which typically targets DNA, and is
either administered alone or in combination therapies.3
However, both intrinsic and acquired Pt-resistances are
major clinical concerns,4−6 requiring the development of
drugs that circumvent this problem by possessing an
alternativeor multitargetedmechanism of action (MoA).
Other precious metals have promising anticancer activity,
including organo-Os (complexes that, unlike cisplatin, do not
have DNA as their major target). Speciﬁcally, some Os(II)
“piano-stool” (metal-arene “half-sandwich”) complexes have
been shown to exhibit nanomolar potency against cancer cells7
and yet also low in vivo toxicities.8 The “piano-stool” structure
of such complexes allows medicinal chemists to ﬁne-tune the
biological properties of the complex by careful manipulation of
coordinated ligands, resulting in a wide range of diﬀerent
cellular mechanism(s) of action, not limited to redox
modulation (both oxidative and reductive stress),9,10 DNA
binding, or protein kinase inhibition.11 Higher oxidation state
complexes of osmium also show clinical promise, with
potential both in vitro and in vivo.12 The mechanism of action
of Os(VI) nitrido complexes developed by Lippard et al.
depends greatly on the choice of ligands; structurally similar
complexes activate either p53-dependent or p53-independent
cell death pathways, depending on the nature of the
coordinated ligands.13
We have previously reported two interesting classes of
osmium(II) arene anticancer complexes with diﬀerent
chemical properties: osmium−sulfonamide transfer hydro-
genation catalysts, which can convert pyruvate to lactate in
cells,10 and highly potent osmium-azopyridine complexes,
which generate reactive oxygen species (ROS) in cancer
cells.7,14 Intrinsic levels of ROS are frequently elevated in
cancer cells, typically arising from mitochondrial dysfunction
and the higher metabolic activity associated with tumor
proliferation and metastasis.15 However, further oxidative
stress is known to cause cell cycle arrest and apoptosis,16−19
which therefore presents a novel chemotherapeutic target that
could render selectivity toward cancer cells.20 In this work, we
compare the antiproliferative activity of these previously
reported classes of Os(II) compounds,10,21 their ability to
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generate reactive oxygen species (ROS) in both cancer cells
and in vivo, as well as their remarkable selectivity and potential
for circumventing Pt-resistance.
The 16e Os(II) arene sulfonamide transfer hydrogenation
catalysts 1−8 can convert pyruvate to lactate in cells.10 The
highly potent 18e azopyridine complexes are much less reactive
(especially the relatively inert iodido complexes) and appear to
be activated inside cells and target mitochondria.14,21 We have
compared the potency and selectivity of these two classes of
complexes toward cells in culture and their in vivo toxicity in
zebraﬁsh (Danio rerio) embryos as a high-throughput
vertebrate model,22,23 considered to be a predictor for drug
toxicity in humans.24−26 Unlike rodent models, zebraﬁsh
embryos are easy to handle, inexpensive, and useful for the
study of solubilized compounds without consideration
required for formulation or route of delivery. We investigated
the MoA of the osmium(II) complexes in 2D cell culture and
show how it translates into the in vivo zebraﬁsh model. The
zebraﬁsh genome has been sequenced, and ca. 75% of human
genes have at least one zebraﬁsh orthologue.26 Zebraﬁsh
embryos share developmental phenotypes with mammals, and
many biochemical pathways are conserved.27 In fact, zebraﬁsh
have been used to identify cell cycle inhibitors28 and
compounds that activate the p53 pathway, inducing
apoptosis.29 Furthermore, the correlation between cardio-
toxicity and hepato-toxicity in zebraﬁsh and preclinical
mammalian models is well established.30 Toxicity studies of
Ru(II) and Ir(III) complexes in zebraﬁsh have been
reported,31−34 but this study appears to be the ﬁrst on Os(II)
complexes. We have synthesized a ﬂuorescently labeled
complex that has enabled the in vivo biodistribution of Os to
be compared with the site(s) of ROS generation. This work
reveals the critical roles of the ligands in determining the
anticancer potency of complexes including their mechanism of
action, toxicity, and selectivity and has allowed identiﬁcation of
complexes with potential for clinical development. Speciﬁcally,
we investigate the translation of the mechanism of action and
accumulation of Os(II) arene complexes from in vitro cellular
studies to a readily available in vivo model.
■ RESULTS
Sulfonamide complexes 1−5 and 7−8 and azopyridine
complexes 9−13 (Scheme 1) have been previously reported
and are known to be stable in aqueous media.10,21 In addition,
a novel rhodamine-conjugated sulfonamide-diphenyl-ethyl-
enediamine ligand L6 was synthesized by the reaction between
rhodamine sulfonyl chloride and the chiral diamine (see
Supporting Information). Complex 6, containing ligand L6,
was synthesized as a dark purple solid in a biphasic reaction
(dichloromethane/water) with the dimer [(η6-p-cymene)-
OsCl2]2 and a base (potassium hydroxide), yielding a dark
purple solid.
In Vitro Antiproliferative Activity. Antiproliferative
activities (IC50 values, concentrations that inhibit 50% of cell
growth) toward nine human cell lines were determined for
complexes 1−13 by investigating cell viability after drug
exposure (24 h + 72 h recovery time) using the SRB assay, and
compared to the anticancer drug, cisplatin. The nature of the
N,N-bidentate ligand is crucial to the anticancer activity in
three parental cancer cell lines, A2780 (ovarian), A549 (lung),
and HCT116 (colon), as can be seen in Tables S1 and S2.
Sulfonamide complexes 1−8 have lower antiproliferative
activity compared to cisplatin (IC50 4.4−30 μM in A2780,
compared to 1.2 μM for cisplatin), while azopyridine
complexes 9−13 were highly potent, achieving, in some
cases, nanomolar potency (IC50 140 nM for 13 in A2780).
Generally, both series of Os(II) arene complexes were most
potent toward A2780 ovarian cancer cells and least potent
toward HCT116 colon cancer cells (Figure 1a, Table S1).
The η6-arene also inﬂuences the antiproliferative properties
of the complexes, with higher activities achieved upon arene
extension (p-cymene < biphenyl < m-terphenyl) in both the
sulfonamide (2 < 7 < 8) and azopyridine (9 < 11; 10 < 12)
series. This is probably due to increased hydrophobicity,
although this does not always translate directly to increased
cellular accumulation and improved anticancer potency since
uptake mechanisms can involve active/energy-dependent
pathways as well as passive diﬀusion. Nonetheless, the
observed trend has been noted previously for other N,N′-
chelated Os(II) arene “piano-stool” complexes.35 Furthermore,
exchange of Cl for I in piano-stool azopyridine complexes 9−
13 further enhanced the potency (9 < 10; 11 < 12), in some
cases by nearly 2 orders of magnitude (in A549 cells: complex
11, IC50 20 ± 1 μM, compared to 12, IC50 0.27 ± 0.03 μM).
Since halide exchange can modify cellular uptake and
accumulation pathways involved in the ﬁrst stages of drug
action,36 such a potency increase by halide exchange may be
attributed to the triggering of diﬀerent apoptotic pathways as a
consequence of diﬀerential compartmentalization and/or
target recognition of the complexes once they have reached
intracellular space.37 Previous reports show that complex 1
accumulates in the cytoplasm,10 while complex 10 locates in
mitochondria.38
In the clinic, ovarian cancers are commonly treated with
platinum complexes;39 however, both intrinsic and acquired
resistance mechanisms reduce the eﬃcacy of platinum
therapies. The ability of Os(II) arene complexes to circumvent
Pt resistance mechanisms and maintain activity in Pt-resistant
cell lines was ﬁrst investigated using A2780 Cis (cisplatin-
resistant) cancer cells. Resistance factors were determined as
the ratio between IC50 values for Pt-resistant cells and parental
cells (Figure 1b, Table S2), which provide an indication as to
Scheme 1. Osmium(II) Sulfonamide Complexes 1−8 and
Azopyridine Complexes 9−13 Studied in This work (p-cym
= para-Cymene)
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whether it is possible for a given complex to maintain its
potency in the platinum-resistant cell line. No reduction in
potency was observed for any of the azopyridine complexes 9−
13 in the Pt-resistant cell line, with the exception of chlorido
complex 11 (3.9 ± 0.3 μM in A2780, 16.8 ± 0.2 μM in A2780
Cis). In the sulfonamide series, only complexes 3 and 4
maintained their antiproliferative potency in the Pt-resistant
cell line (Figure 1b), showing that the nature of the N,N-
chelating ligand, arene, and halide ligand all contribute to the
overall biological properties of the complex. Azopyridine
complexes 9−13 may have diﬀerent uptake and eﬄux
pathways compared to cisplatin and a mechanism of action
that is not DNA-based.14
Further insights into the behavior of these Os(II) complexes
at the cellular level can be gained by determination of osmium
accumulation in the presence or absence of verapamil, a
compound known to inhibit the transporter P-glycoprotein
(PgP), which is associated with multidrug-resistant cells.40
Complex 1 appeared to undergo detoxiﬁcation by PgP-
promoted cellular eﬄux (P < 0.05), as well as complex 10
but to a lesser extent (see Supporting Information). This
demonstrates how the bidentate ligand can aﬀect cellular
accumulation via biochemical interactions experienced by
metal complexes in cells.
Pt-resistance at the cellular level is also related to the
presence/absence of mutations in particular oncogenes, such
as p21 and p53. Maintaining anticancer activity in cells with
such mutations is particularly important since they are present
in ca. 50% of cancers.41 The dependence of activity on the
tumor suppressor P53 was investigated using HCT116p53−/−
(P53 knockout) cancer cells (Table S2). While the P53 status
aﬀected some of the antiproliferative activities of the osmium
complexes, the activity of some osmium azopyridine complexes
was unaﬀected (complex 13: 0.15 ± 0.01 μM in the parental
HCT116 cell line, compared to 0.13 ± 0.01 μM in p53−/−
cells). For many of the azopyridine complexes, the signiﬁcance
was minor when compared to Pt drugs; cisplatin was almost an
order of magnitude less active (36.7 μM) in the P53 knockout
cell line. Similarly, dependence of activity on the tumor
suppressor P21 was investigated in HCT116p21−/− (P21
knockout) cancer cells (Table S2). All complexes investigated
(1−13 and cisplatin) showed lower activities in the P21
knockout cell line. Interestingly, in the case of HCT116Ox
(oxaliplatin-resistant) colorectal cancer cells, both sulfonamide
and azopyridine complexes all appeared to overcome Pt-
resistance. In contrast, cisplatin was 4.5× less active in the Pt-
resistant line. However, all osmium complexes were typically
less active against the colorectal cancer cells (Figure 1a).
Antiproliferative activities in ovarian (A2780) and lung
(A549) parental cancer cell lines were compared to data
obtained in primary ovarian (HOF) and lung (MRC5)
ﬁbroblasts, models for noncancerous cells. Ratios between
the anticancer activities in normal cells and cancer cells often
provide an early indication of the possible therapeutic window
for a given developmental drug, and the values are particularly
relevant when compared to those of standards of care
medications determined under the same experimental
conditions. All Os(II) complexes typically showed good
Figure 1. Half-maximal inhibitory concentrations (IC50, μM) for Os(II) complexes 1−13 and cisplatin (CDDP). (a) IC50 values for 1−13 span 2
orders of magnitude; highest activity is toward A2780 ovarian carcinoma (blue) compared to A549 lung carcinoma (green) and HCT116 colorectal
carcinoma (yellow) cells. (b) Os(II) arene complexes can overcome Pt-resistance. Resistance ratios for complexes 1−13 and CDDP (IC50 in
A2780/IC50 in A2780cis cisplatin-resistant cells). Azopyridine complexes 9−13 (striped) show particular promise for overcoming Pt-resistance in
ovarian cancer cells. (c) Os(II) arene complexes are selective for A2780 ovarian cancer cells over noncancerous HOF healthy ovarian ﬁbroblasts
(IC50 in HOF/IC50 in A2780). See Tables S1 and S2 for full numerical data.
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selectivity between cells of ovarian origin, achieving up to 15×
selectivity in the case of 10 (0.15 ± 0.01 μM in A2780
compared to 2.32 ± 0.01 μM in HOF), twice as selective as
cisplatin (8.5×). In contrast, the anticancer selectivity between
lung cells was much less apparent, ca. 4× for 10 (1.1 ± 0.2 μM
in A549 compared to 4.5 ± 0.3 μM in MRC5), similar to
cisplatin (Tables S1 and S2).
In Vitro Generation of Reactive Oxygen Species.
Osmium azopyridine complexes have been shown to localize in
the mitochondria of ovarian cancer cells using synchrotron X-
ray ﬂuorescence.38 Furthermore, investigations into their
mechanism of action indicate that the generation of reactive
oxygen species (ROS) in cancer cells is highly relevant to their
anticancer activity.14 In particular, for complex 10 RNA-seq
data shows time-dependent activation of cellular pathways that
link the generation of ROS to the observed mechanism of
action and subsequent cell death.14 We investigated the
generation of reactive oxygen species (ROS) by sulfonamide
complex 1 compared to azopyridine complexes 9 and 10.
Although 1 is signiﬁcantly less active than the azopyridine
derivatives, all Os(II) complexes generated similar high levels
of ROS and superoxide in A2780 human ovarian cancer cells
upon exposure to equipotent drug concentrations (Figure 2
and Table S3).
We then investigated the generation of ROS in non-
cancerous HOF human ovarian ﬁbroblasts (Table S4).
Interestingly, the generation of ROS was signiﬁcantly lower
than that observed in A2780 cancer cells for both Os(II)
azopyridine and sulfonamide complexes. The Q2 population
(superoxide and ROS) decreased from 96% to 38%, as we
observed previously using MRC5 normal lung ﬁbroblast cells
exposed to 10.9,14 Normal cells are known to tolerate increased
levels of oxidative stress better than cancer cells, and so
selective generation of ROS in ovarian cancer cells can provide
a novel targeted approach to chemotherapy, exploiting a key
vulnerability of cancer cells.42
Electrochemical Investigations of Osmium Azopyr-
idine Complexes. Due to the clear involvement of ROS in
the mechanism of action of complex 10, the electrochemical
behavior of p-cymene complex 10 (red) and structurally
Figure 2. Detection of reactive oxygen species (ROS) by ﬂow cytometry in A2780 cancer cells treated with Os-sulfonamide 1 or Os-azopyridine 10
for 24 h (1 × IC50) compared to untreated control. FL1 channel, total ROS (including hydrogen peroxide, hydroxyl-radicals and nitro-radicals);
FL2 channel, superoxide. See SI for full numerical data.
Figure 3. (a) Structure of Os(II) sulfonamide 6 bearing rhodamine ﬂuorescent marker (red). (b) Three-dimensional ﬂuorescence spectrum of
Os(II) sulfonamide complex 6 in acetonitrile, acquired using a Jasco FP-6500 Fluorimeter. (c) Confocal microscopy in A2780 cancer cells:
containing with Os complex 6 (red) and ROS detection reagent (green) indicates the generation of ROS inside cells. Cells were stained using the
green reagent of the ROS/Superoxide Detection Kit (Enzo life sciences) to detect ROS. Excitation, 458 and 488 nm; green emission for ROS,
493−550 nm.
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similar biphenyl complex 12 (blue) were studied by cyclic
voltammetry (CV) using Ag/AgCl (0.21 V) as the reference
electrode to determine ligand/metal based reduction poten-
tials. The CVs of the two complexes (−2.0 V to +2.0 V; 100
mV/s; 10−3 M; CH3CN; see Figure S2) are in accordance with
experimental CVs reported for structurally close arene osmium
complexes.43 Both complexes 10 and 12, containing the strong
π-acceptor ligand azpy, are reduced via two consecutive one-
electron steps, with simultaneous loss of the halide ligand (Cl
and I, respectively): The ﬁrst reduction step (ca. −0.4 V) is
electrochemically reversible (Figure 3b), with no loss of halide,
whereas the second step is strongly dissociative with respect to
the halide ligand. Thus, the redox mechanism of both
complexes is an EEC mechanism (E, one-electron transfer at
the electrode; C, chemical step, here, halide dissociation).
To investigate the redox behavior of both complexes in a
biologically relevant range of potentials, CV spectra of 10 and
12 were monitored between −0.7 V and +0.7 V (Figure S3).
Interestingly, for both complexes, the ﬁrst one-electron step,
without simultaneous loss of the halide ligand, is observed at a
potential accessible for biological reductants. In this range of
potentials, the absence of the second reduction wave allows the
complexes to remain intact (no structural changes). This study
suggests that ligand-centered redox processes of complexes 10
and 12 may be responsible for the ROS production in cancer
cells. Further evidence of the link between ROS generation and
the mechanism of action of complex 10 is its ability to produce
OH radicals, which have been trapped using electron
paramagnetic resonance (EPR) spectroscopy.44
Confocal Microscopy in Cancer Cells. To investigate
cellular localization and further probe the mechanism of action,
we synthesized a red-ﬂuorescent Os(II) complex (6, Figure 3a)
derived from complex 1. Such a red ﬂuorescent complex
facilitates coimaging of complex localization (red) and ROS
generation (using the green-ﬂuorescent ROS detection reagent
in ﬂow cytometry studies, Figure 2). Previous work has shown
that R2 substituents have little eﬀect on the antiproliferative
properties of complexes 1−5,10 and this was also the case for
complex 6 (Figure 1). Optimal absorption and emission
wavelengths for ﬂuorescence studies were determined (ex/em
= 560/580 nm, Figure 3b). Perhaps surprisingly, ﬂuorescence
was not quenched by Os in the complex, unlike in several
previous reports of labeling transition metal complexes.45
Next, A2780 cancer cells were treated with red-ﬂuorescent
complex 6 (Figure 3a) and then stained with the green ROS-
detection reagent (Enzo Life Sciences, Figure 3c) previously
used in our ﬂow cytometry investigations (Figure 2). The two
emission bands were readily resolved, and clear colocalization
(yellow) was observed between green (ROS production) and
red (complex 6) ﬂuorescence. These data provide validation of
previous cellular metal accumulation studies using ICP-MS and
ROS generation studied by ﬂow cytometry. Moreover, these
images further implicate ROS production as a major
contributor to the mechanism of action of such Os(II) arene
complexes.
In Vivo Toxicity Studies. Since the compounds showed
promise in vitro, in vivo toxicities were investigated using
zebraﬁsh embryos, following the well-established zebraﬁsh
embryo toxicity (FET) test (Figure 4). Strikingly, the osmium
complexes (1−13) were all less toxic, by up to 40× in the case
of 10, toward zebraﬁsh embryos compared to the anticancer
drug cisplatin (LC50 = 0.6 ± 0.2 μM in SG-WT) in all three
wild-type strains (AB, SG, and TU). Comparable activities
were determined between wild-type embryos, suggesting that
the origin of the strain selected for future study would not
inﬂuence subsequent experimentation. A second-generation
platinum anticancer drug, carboplatin, was found to be an
order of magnitude less toxic than cisplatin (LC50 = 5.7 ± 0.9
μM in SG-WT) toward zebraﬁsh. The lower toxicity of
carboplatin (especially nephrotoxicity, ototoxicity, and neuro-
toxicity) is well documented in human clinical trials.
Interestingly, Os(II) azopyridine complexes were signiﬁcantly
less toxic than sulfonamide complexes, displaying low toxicity
(LC50 = 24.3 ± 0.4 μM in the case of complex 10 against SG-
WT embryos) in zebraﬁsh (Figure 4 and Table S5).
In Vivo Generation of Reactive Oxygen Species: Does
an in Vitro Mechanism of Action Translate to an in Vivo
Animal Model? Since the in vitro mechanism of action of
both Os(II) azopyridine and sulfonamide complexes appears
to be strongly related to the generation of superoxide and ROS
in cultured cancer cells, we investigated the translation of such
mechanism of action to an in vivo model using zebraﬁsh (Danio
rerio) following an adapted literature procedure.46,47 Whole-
mount zebraﬁsh embryos were exposed to equipotent solutions
of Os(II) complexes 1 and 10 (1.0 × LC50) for 96 h and
anaesthetized, then levels of reactive oxygen species were
determined using a green ﬂuorescent probe to detect ROS
Figure 4. LC50 concentrations (μM) for osmium complexes 1−13 and Pt anticancer drugs (cisplatin and carboplatin) determined in three zebraﬁsh
(Danio rerio) embryo wild-type strains: Singapore (SG), Tubingen (TU), and AB-wild type. (a) Trends in acute toxicity are maintained in all three
wild-type strains of zebraﬁsh embryo. (b) All osmium arene complexes are less toxic (higher LC50) than CDDP. See Table S5 for full numerical
data.
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(including H2O2, peroxynitrite, and hydroxyl radicals) and
analyzed using confocal microscopy.
Good dye localization was observed in the positive control
(4 dpf zebraﬁsh exposed to 50 μM rotenone for 5 min).
Complexes 1 and 10 generated elevated levels of ROS in vivo
in a concentration-dependent manner. ROS generated by
treatment with Os-sulfonamide 1 appeared to locate largely in
the swim bladder, whereas Os-azopyridine 10-generated ROS
were more broadly distributed across the organism (Figure 5).
Though the drug concentration was an order of magnitude less
for 1 (2.4 μM compared to 24.3 μM), the levels of ROS appear
qualitatively higher than in those treated with 10, which may
be related to the radical induction eﬃciency.
Interestingly, complex 1 can catalyze transfer hydrogenation
reactions in cells using formate as a hydride source, perturbing
the cellular redox balance.10 Micromolar levels of formate are
present in human serum,48 and while formate biochemistry in
zebraﬁsh is not fully understood, humans and zebraﬁsh share
similar one-carbon pathways.49 The catalytic properties of 1
may explain why ROS were present in qualitatively greater
amounts, despite the administered concentration of 10 being
an order of magnitude greater.
Figure 5. Reactive oxygen species (ROS) in anaesthetized whole-mount Singapore wild-type zebraﬁsh (Danio rerio) treated with equipotent
concentrations (1 or 2× LC50) of Os-sulfonamide 1 or Os-azopyridine 10 for 96 h. Fluorescence for ROS (green) is shown superimposed onto
bright ﬁeld images. Embryos were stained using the green reagent of the ROS/Superoxide Detection Kit (Enzo life sciences) to detect ROS.
Excitation, 458 and 488 nm; green emission for ROS, 493−550 nm. Rotenone was the positive control; 50 μM, 2 min exposure.47
Figure 6. Two-color ﬂuorescent imaging of whole mount SG-WT zebraﬁsh (Danio rerio) treated with Os(II) sulfonamide 6 for 96 h. Fluorescence
for ROS (green) and 6 (red) is shown superimposed onto bright ﬁeld images. Overlapping regions (yellow) are shown. Confocal images were
acquired using a Zeiss LSM880 confocal microscope. Embryos were stained using the green reagent of the ROS/Superoxide Detection Kit (Enzo
life sciences) for ROS detection. Excitation, 458, 488, and 561 nm; green emission for ROS, 493−550 nm; red emission for 6, 568−750 nm. See SI
for full confocal data.
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Since ROS were highly localized in zebraﬁsh treated with 1,
we explored methods for determining drug localization in vivo.
Laser ablation coupled to inductively coupled plasma mass
spectrometry (LA-ICP-MS),50 nanoscale secondary ion mass
spectrometry (nanoSIMS) imaging,51 and electron micros-
copy52 have been explored for the detection of metal ions and
nanoparticles in zebraﬁsh. Confocal microscopy and ﬂuores-
cent complex 6 provide an alternative strategy, which utilizes
the transparent properties of zebraﬁsh embryos. Zebraﬁsh
treated with red-ﬂuorescent osmium complex 6 showed red
ﬂuorescence, indicative of in vivo complex localization.
Remarkably, the in vivo distribution of ROS was similar to
the internal localization of 6, as shown by the yellow areas
(Figure 6), implicating the complex in the production of ROS.
When taken with the statistically similar in vitro and in vivo
activities of 1 and 6, it appears that the ﬂuorescent marker had
little inﬂuence on the biological interactions of the complex.
These studies conﬁrm the high anticancer potency of
osmium azopyridine complexes.21,53 Elevated levels of ROS
were detected in A2780 cancer cells treated with nanomolar
concentrations of 10 (Figure 2, Table S3); yet at micromolar
concentrations, signiﬁcantly lower levels were detected in
noncancerous ﬁbroblasts and in vivo in zebraﬁsh (Table S4),
despite the more than an order of magnitude higher dosage.
■ DISCUSSION AND CONCLUSIONS
Whereas half-sandwich osmium(II) arene azopyridine com-
plexes can exhibit highly potent anticancer activity,21,53
sulfonamide complexes showed only moderate activity, high-
lighting the important role played by the N,N-bidentate ligand.
In the cell lines investigated in this study, the osmium
complexes exhibited highest potency against A2780 ovarian
cancer cells, achieving nanomolar potency, compared to lower
potency of previously reported Ru(II) analogues (IC50 2−6
μM, depending on azopyridine ligand and η6-arene).54 In the
clinic, ovarian cancers are commonly treated with platinum
anticancer complexes;39 however, both intrinsic and acquired
resistance mechanisms reduce the eﬃcacy of platinum-based
therapies, highlighting the importance for the development of
anticancer agents that operate by alternative mechanism(s) of
action.5 Remarkably, azopyridine complexes 9−13 were found
to circumvent cisplatin resistance, determined by comparing
antiproliferative activities in A2780cis cisplatin-resistant cells
compared to parental A2780 cells, and HCT116Ox oxaliplatin-
resistant cells and parental HCT116 cells. In contrast,
sulfonamide complexes appeared to share common resistance
mechanisms with cisplatin, reﬂected by their lower potencies
toward platinum-resistant cells compared to platinum-sensitive
cells. The mechanisms of acquired resistance, particularly
between A2780 and A2780 Cis resistant cells are well
established. These include reduced cellular uptake and
increased cellular eﬄux (both of which result in reduced
cellular accumulation), as well as increased DNA repair.
Hence, it is reasonable to hypothesize that azopyridine
complexes 9−13 may have diﬀerences in uptake and eﬄux
pathways compared to cisplatin and a mechanism of action,
which is not DNA based, centered on ROS induction.
Similarly, the P21/P53 status was not found to aﬀect
antiproliferative activities to the same extent as for cisplatin
(over an order of magnitude activity decrease in the P53
knockout cell line). Maintaining anticancer activity in cell lines
that have mutations in p53 is important, as it is well established
that such a mutation is present in approximately 50% of all
colorectal cancers.41 Clinical cases are prime examples of
inherent platinum resistance. Taken together, these data
suggest that the in vitro mechanism of action for Os-arene
complexes, particularly for complexes bearing an azopyridine
ligand, diﬀers greatly from current platinum-based therapies55
and that they could be further developed to target both
acquired and inherent platinum resistance.
The selective generation of reactive oxygen species in cancer
cells has been suggested as a novel targeted approach to
chemotherapy, which exploits a key vulnerability of cancer
cells.42 When exposed to either complex 1 [Os(p-cymene)-
(TsDPEN)] or 10 [Os(p-cymene)(AzPy-NMe2)I]
+ in an
equipotent manner, comparable levels of ROS/superoxide
were detected in A2780 cancer cells (Table S1: 96 ± 1 and
95.4 ± 0.2%, respectively), indicative of a common mechanism
of action for piano-stool osmium complexes involving redox
modulation. However, in noncancerous ovarian ﬁbroblasts,
sulfonamide complex 1 generated signiﬁcantly more ROS (FL1
channel) than azopyridine complex 10 (Table S2), suggesting
that the nature of the N,N-bidentate ligand is crucial to the
biological activity of the complexes and highlighting the
eﬃcacy of azopyridine complexes, which may exhibit fewer
side eﬀects if excessive ROS production is selective for cancer
cells.
To conﬁrm internalization of the osmium complex in vivo,
ﬂuorescent rhodamine complex 6 was synthesized and
investigated in vivo using confocal microscopy. The localization
of the complex in zebraﬁsh embryos correlated well with
oxidative stress, further implicating the involvement of the
osmium complex in the production of ROS.
Elevated levels of ROS were detected in A2780 cancer cells
treated with nanomolar concentrations of 10 (Figure 2, Table
S3); yet at micromolar concentrations, signiﬁcantly lower
levels were detected in vitro using noncancerous ﬁbroblasts and
in vivo using zebraﬁsh (Table S2), despite the more than an
order of magnitude higher dosage. In these experiments,
azopyridine complex 10 has shown clinical promise for the
selective generation of oxidative stress in cancer cells over
noncancerous cells and, to a lesser extent, in a whole organism
model. Beyond using zebraﬁsh as a toxicity model, future work
might investigate the eﬃcacy of complex 10 in tumor-bearing
zebraﬁsh since 10 has previously been shown to delay the
growth of xenografts (HCT116 human colorectal cancer cells)
in mice.8 In agreement with our ﬁndings using zebraﬁsh, few
toxic side eﬀects were observed in the xenograft-bearing mice,
reﬂected in a lack of clinical toxicity signs mice.8 Overall, it is
apparent that the nature of the chelated ligand is highly
inﬂuential over the biological properties of the complexes and
crucially over the selective generation of reactive oxygen
species in cancer cells compared to normal cells and living
organisms. Determination of metallodrug speciation in a
biological environment is crucial for further understanding of
both the mechanism of action and the design of future metal-
based anticancer agents.
■ EXPERIMENTAL SECTION
Materials. Osmium trichloride trihydrate was obtained from
Heraeus South Africa Ltd. and Heraeus GmbH. (1R,2R)-Diphenyle-
thylenediamine was purchased from Arran Chemical Company
(Ireland). Ascorbic acid, carboplatin, cisplatin (CDDP), dimethyl
sulfoxide (DMSO), sodium chloride, sulforhodamine B acid chloride,
tricaine (4 mg·mL−1 tricaine powder in doubly deionized water,
adjusted to pH 7 using Tris base), and thiourea were purchased from
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Sigma-Aldrich (UK). Magnesium sulfate, potassium hydroxide, and all
nondried solvents were purchased from Fischer Scientiﬁc. Hanks
Balanced Salt Solution (HBSS) was purchased from Scientiﬁc
Laboratory Supplies. ROS/superoxide detection kit was purchased
from Enzo Life Sciences (UK). Hoechst-33258 and Alexa Fluor 633
Phallodin were purchased from ThermoFischer. Concentrated nitric
acid (72% v/v) was freshly distilled before use. All reagents were used
as received unless speciﬁed. Singapore wild-type (SG-WT) zebraﬁsh
were maintained in reverse-osmosis (RO) water supplemented with
Aquavitro salt (pH 7.5). GEMMA micro powder food for zebraﬁsh
was purchased from Skretting. Live food (Artemia salina) was
purchased from ZM Fish Food.
Instrumentation. Mass Spectrometry (HR-MS). Low resolution
ESI-MS spectra for ligand L6 and complex 6 dissolved in acetonitrile
were obtained using an Agilent 6130B ESI mass spectrometer. High
resolution mass spectra were kindly acquired by Dr. L Song and Mr.
Phillip Aston using a Bruker UHR-Q-TOF MaXis, with a positive ion
scan range of m/z 50−3000. Analysis was carried out through direct
infusion (2 μL/min) with a syringe pump, with sodium formate (10
mM) calibration. Source conditions, ESI (+); end plate oﬀset, −500
V; capillary, −3000 V; nebulizer gas (N2), 0.4 bar; dry gas (N2), 4 L/
min; dry temperature, 453 K; funnel RF, 200 Vpp; multiple RF, 200
Vpp; quadruple low mass, 55 m/z; collision energy, 5.0 eV; collision
RF, 600 Vpp; ion cooler RF, 50−250 Vpp ramping; transfer time, 121
μs; prepulse storage time, 1 μs.
Elemental Analysis (CHN). Elemental analysis for ligand L6 and
complex 6 was carried out by Warwick Analytical Services UK on an
Exeter elemental analyzer CE440.
Nuclear Magnetic Resonance Spectroscopy (NMR). Spectra for
ligand L6 and complex 6 were acquired for CD3CN solutions in 5 mm
NMR tubes (Sigma-Aldrich, UK). 1H, COSY, and 13C NMR spectra
were recorded using a Bruker HD-500 NMR spectrometer using
standard pulse sequences. Chemical shifts were referenced to residual
solvent and processed using Topspin 3.2 (Bruker, UK).
Inductively Coupled Plasma Optical Emission Spectroscopy
(ICP-OES). Data were obtained using a PerkinElmer Optima 5300 DV
Optical Emission Spectrophotometer, using a calibration range from
50 to 700 ppb, freshly prepared in 3.6% v/v nitric acid containing
thiourea (10 mM) and ascorbic acid (100 mg/L) to stabilize osmium
in nitric acid solution.56 Samples were diluted accordingly, and the
salinity of the calibration adjusted to match the matrix of the samples
by standard addition of sodium chloride solution. Os (λ = 225.585,
228.226 nm), Ir (λ = 208.882, 237.277 nm), and Pt (λ = 265.945,
204.937 nm).
Inductively Coupled Plasma Mass Spectrometry (ICP-MS). ICP-
MS data were obtained using either an Agilent 7500 series or Agilent
7900 series ICP-MS with an internal standard of 166Er (50 ppb) in
both no-gas and He-gas mode. Calibration standards for Os (0.1−
1000 ppb) were freshly prepared in 3.6% v/v nitric acid containing
thiourea (10 mM) and ascorbic acid (100 mg/L) to stabilize osmium
in nitric acid solution.56 Data were acquired and processed using
Agilent ChemStation for Windows (7500 series ICP-MS) or Agilent
Mass Hunter 4.3 for Windows (7900 series ICP-MS).
Three-Dimensional Fluorescence Spectroscopy. Spectra for
complex 6 (dissolved in acetonitrile, ∼0.01 mM) were acquired
using a Jasco FP-6500 Fluorimeter, with path length of 1 cm.
Confocal Microscopy (Cancer Cells). A2780 cancer cells treated
with Os(II) complex 6 (0.5 × and 1.0 × IC50; 24 h exposure) were
washed with PBS and stained using green ROS detection reagent (2
μM, Enzo Life Sciences). Cells were analyzed using a Zeiss LSM880
confocal microscope (Argon laser; excitation, 458, 488, and 561 nm;
green emission for ROS, 493−550 nm; red emission for complex 6,
568−750 nm). Data were processed using Zen 2.3 for Windows.
Confocal Microscopy (Zebraﬁsh). Whole-mount zebraﬁsh were
analyzed using a Zeiss LSM880 confocal microscope (Argon laser;
excitation, 458, 488, and 561 nm; green emission for ROS, 493−550
nm; red emission for complex 6, 568−750 nm). Data were processed
using Zen 2.3 for Windows.
Chemical Synthesis. The synthesis and full characterization of
complexes 1−5 and 7−13 have been previously reported.10,21 The
purity of all compounds determined by C, H, and N combustion
elemental analysis was ≥95%.
2-(3-Diethylamino-6-diethylazaniumylidene-xanthen-9-yl)-5-(N-
(2-amino-1,2-diphenyl-ethyl)sulfonoyl)-benzenesulfonate (Ligand
L6). (1R,2R)-1,2-Diphenylethylenediamine (112 mg, 0.58 mmol, 1
mol equiv) and triethylamine (117 mg, 160 μL, 1.16 mmol, 2 mol
equiv) were dissolved in dichloromethane (2 mL) at 273 K.
Sulforhodamine B acid chloride (400 mg, 0.69 mmol, 1.2 mol
equiv) in dichloromethane (2 mL) was added dropwise over 3 h. The
solution was washed with water (10 × 25 mL) and aqueous fractions
extracted with dichloromethane (3 × 10 mL). Organic fractions were
dried over magnesium sulfate, and the solvent was removed to yield a
dark purple amorphous solid (78.6 mg, 0.104 mmol, 18%). 1H NMR
(500 MHz, CD3CN, 25 °C, TMS): δ = 8.43 (s, 1H, ArH), 7.49 (m,
1H, ArH), 7.38 (m, 1H, ArH), 6.88−7.35 (m, 14H, ArH), 6.81 (m,
2H, ArH), 4.55 (d, 3J(H,H) = 7.4 Hz, 1H, CHNH), 4.15 (d, 3J(H,H)
= 7.4 Hz, 1H, CHNH), 3.58−3.73 (m, 8H, CH2), 1.24−1.33 (m,
12H, CH3).
13C NMR (125 MHz, CD3CN, 25 °C, TMS) δ 158.8,
158.2, 156.0, 148.4, 143.0, 142.6, 139.6, 133.5, 133.4, 130.0, 128.6,
128.5, 128.3, 128.2, 127.8, 127.6, 127.5, 127.4, 127.4, 127.3, 127.0,
126.8, 113.6, 95.9, 65.1, 61.2, 60.2, 59.8, 50.0, 12.2. UV/vis: λmax 557,
399, 353, 307, 281, 258 nm. HRMS (m/z): [M + H]+ calcd. for
C41H45N4O6S2, 753.2775; found, 753.2769. Analysis (calcd., found for
C41H44N4O6S2): C (65.40, 65.05), H (5.89, 6.04), N (7.44, 7.62).
[Os(η6-p-Cymene)(SrbDPEN)] (Complex 6). [Os(η6-Biphenyl)-
Cl2]2 (15.7 mg, 0.02 mmol, 1 mol equiv) and (1R,2R)-SrbDPEN
(30 mg, 0.04 mmol, 2 mol equiv) were stirred in chloroform (5 mL)
with freshly ground potassium hydroxide (22.4 mg, 0.40 mmol, 20
mol equiv) for 5 min, after which time water was added (10 mL) with
vigorous stirring for a further 10 min. The organic layer was washed
with water (3 × 10 mL) and concentrated under reduced pressure to
yield a purple oil, which was dissolved in the minimum amount of
dichloromethane, and a dark purple solid precipitated using n-pentane
(13 mg, 0.012 mmol, 61%). 1H NMR (500 MHz, CD3CN, 25 °C,
TMS): δ = 6.70−8.64 (m, 19H, ArH), 6.14 (d, 3J(H,H) = 5.5 Hz, 1H,
Os-ArH), 6.03 (d, 3J(H,H) = 5.5 Hz, 1H, Os-ArH), 5.90 (m, 2H, Os-
ArH), 4.40 (s, 1H, CHNTs), 3.96 (d, 3J(H,H) = 4.4 Hz, 1H,
CHNH), 3.55−3.74 (m, 8H, CH2), 2.90 (sept, 3J(H,H) = 7.0 Hz, 1H,
CH(CH3)2), 2.31 (s, 3H, CH3), 1.25−1.35 (m, 12H, CH3), 1.23 (d,
3J(H,H) = 7.0 Hz, 6H, CH(CH3)2).
13C NMR (125 MHz, CD3CN,
25 °C, TMS) δ 159.7, 158.2, 156.0, 133.9, 133.7, 133.5, 129.5, 129.3,
128.9, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.7, 127.5,
127.2, 126.9, 126.7, 126.6, 126.1, 113.6, 113.5, 113.4, 95.8, 91.6, 83.6,
81.0, 77.0, 74.1, 73.1, 69.7, 71.2, 68.2, 63.8, 63.2, 58.7, 58.5, 46.0,
45.9, 33.9, 33.0, 31.2, 23.8, 23.3, 23.2, 20.6, 18.6, 12.3. UV/vis: λmax
555, 398, 352, 281, 258 nm. HRMS (m/z): [M + H]+ calcd. for
C51H57N4O6OsS2, 1077.3329; found, 1077.3337. Analysis (calcd.,
found for C51H56N4O6OsS2): C (56.96, 56.82), H (5.25, 5.06), N
(5.21, 4.84).
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jmed-
chem.8b00958.
Experimental details regarding the in vitro and in vivo
biological studies; numerical values for antiproliferative
activity of complexes 1−13 and cisplatin in parental and
resistant cancer cell lines; cell population percentages for
the ﬂow cytometry detection of ROS in A2780 cancer
cell line and HOF human ovarian ﬁbroblasts; LC50
concentrations in three zebraﬁsh embryo wild-type
strains; ROS detection in whole mount SG-WT
zebraﬁsh by confocal microscopy; cyclic voltammetry
studies for complexes 10 and 12; inhibition of PgP-
mediated Os eﬄux by verapamil (PDF)
Molecular formulas strings (XLSX)
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b00958
J. Med. Chem. 2018, 61, 9246−9255
9253
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: I.RomeroCanelon@bham.ac.uk.
ORCID
James P. C. Coverdale: 0000-0002-7779-6620
Nicolas P. E. Barry: 0000-0002-0388-6295
Peter J. Sadler: 0000-0001-9160-1941
Isolda Romero-Caneloń: 0000-0003-3847-4626
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